US regulators said eli lilly and co's weight loss miracle drug is no longer in short supply, with 'substitute' manufacturer Hims & Hers plunging more than 10% during trading.

FDA stated that eli lilly and co's two exenatide-containing GLP-1 injection Zepbound and Mounjaro have been in short supply since 2022 due to increased demand, but the shortage issue is now resolved. Industry organizations say that FDA's determination equals to pharmacies stopping the allocation and distribution of generic versions of the two drugs.

wallstreetcn17:05 ET

Biogen Analyst Ratings

Benzinga14:47 ET · Ratings

Market Whales and Their Recent Bets on REGN Options

Benzinga14:34 ET

Cracking The Code: Understanding Analyst Reviews For Eli Lilly

Benzinga14:00 ET

(REGN) - Analyzing Regeneron Pharmaceuticals's Short Interest

Benzinga13:45 ET

Eli Lilly Analyst Ratings

Benzinga13:15 ET · Ratings